How Much Does Actos (Pioglitazone) Cost in Maryland in 2026?

Maryland Cash Prices for Generic Pioglitazone in 2026

The average cash price for a 30-day supply of generic pioglitazone across Maryland retail pharmacies sits at approximately $15 in 2026. That figure represents a steep drop from early post-patent pricing and from the brand-name Actos list price of roughly $60 per month.

Price variability exists between pharmacy chains. A CVS or Walgreens in Baltimore may quote $12 to $18 for pioglitazone 30 mg #30, while an independent pharmacy in Annapolis or Frederick could charge $10 to $22 depending on its wholesale contract. GoodRx-type discount aggregators frequently show Maryland prices between $8 and $16 for the same quantity. The FDA-approved prescribing information for Actos lists three tablet strengths (15 mg, 30 mg, 45 mg), and in most cases the per-tablet cost is identical across all three strengths, a phenomenon called "flat pricing" that is common among generic thiazolidinediones [1].

Patients paying out of pocket should call at least two pharmacies and check one discount card platform before filling. Prices shift quarterly as wholesalers renegotiate, so the cheapest pharmacy in January may not be the cheapest in June.

Brand-Name Actos vs. Generic Pioglitazone: Price Gap

Brand-name Actos, manufactured by Takeda, carries a list price near $60 per month. Generic pioglitazone costs roughly 75% less. The clinical difference between brand and generic is negligible.

The FDA requires generic pioglitazone to demonstrate bioequivalence to Actos, meaning the active ingredient reaches the bloodstream at the same rate and concentration [2]. A 2012 FDA analysis of 2,070 bioequivalence studies found that generics differed from their brand counterparts by an average of only 3.5% in absorption rate, a margin too small to produce meaningful clinical differences [2]. For Maryland patients, this means switching from Actos to generic pioglitazone saves $45 or more per month with no expected change in glycemic control.

Some patients report subjective differences after switching. If fasting glucose or HbA1c rises after a brand-to-generic switch, the prescriber should investigate adherence, diet changes, and concurrent medications before attributing the change to the formulation itself.

Maryland Medicaid Coverage for Pioglitazone

Maryland Medicaid covers pioglitazone, but the program requires prior authorization (PA) before it will pay for the prescription. The PA process exists because Maryland's Medicaid Pharmacy and Therapeutics Committee places thiazolidinediones on the preferred drug list only after confirming that metformin (the first-line agent per American Diabetes Association 2024 Standards of Care) has been tried or is contraindicated.

To obtain PA approval, the prescriber typically submits documentation showing one of the following: metformin intolerance (e.g., persistent GI symptoms at doses up to 2,000 mg/day), a contraindication such as eGFR <30 mL/min, or clinical rationale for combination therapy. Approval timelines vary, but Maryland Medicaid processes most PA requests within 24 to 72 hours. Emergency fills of up to a 72-hour supply are available at the pharmacy while the PA is pending.

Patients enrolled in a Maryland Medicaid managed care organization (MCO) such as CareFirst, Priority Partners, or Aetna Better Health should verify coverage through their specific MCO formulary, as each MCO can impose additional step therapy or quantity limits beyond the state-level PA requirement.

Insurance Coverage Across Maryland Plans

Most commercial insurance plans in Maryland cover generic pioglitazone on a Tier 1 or Tier 2 formulary position, resulting in copays between $0 and $25 per month for the majority of insured patients. Brand-name Actos, when covered, usually lands on Tier 3 (preferred brand) with copays of $35 to $75.

CareFirst BlueCross BlueShield, the largest insurer in Maryland by enrollment, lists generic pioglitazone on its preferred generic tier. United Healthcare plans sold through the Maryland Health Benefit Exchange similarly classify pioglitazone as a preferred generic. Aetna and Cigna plans available in Maryland follow the same pattern. Kaiser Permanente of the Mid-Atlantic region covers pioglitazone under its generic drug benefit, though Kaiser's closed pharmacy system means the prescription must be filled at a Kaiser pharmacy or through Kaiser's mail-order service.

For patients on Medicare Part D, pioglitazone falls under standard generic coverage. Under the Inflation Reduction Act provisions that took effect in 2025, total out-of-pocket drug spending for Medicare Part D enrollees is capped at $2,000 annually, a ceiling that protects patients who take multiple medications alongside pioglitazone.

Patients whose plans require a higher copay for pioglitazone than expected should ask the pharmacist to run the claim as a generic (using the NDC for generic pioglitazone rather than brand Actos). Pharmacy software occasionally defaults to the brand NDC, which triggers a higher tier copay.

Takeda Savings Card and Generic Manufacturer Programs

Takeda offered a manufacturer copay card for brand-name Actos during its patent-protection years, and some savings programs persist for the brand product. The Takeda savings card, when active, can reduce brand-name Actos copays to as little as $0 for commercially insured patients, with savings capped at a set annual dollar amount.

Generic pioglitazone manufacturers do not typically offer individual savings cards because the drug's price point is already low. The more practical discount path for Maryland patients is a pharmacy discount card or coupon aggregator. Programs such as GoodRx, RxSaver, and SingleCare negotiate cash-price discounts with pharmacy chains and consistently beat the undiscounted cash price. A GoodRx coupon for pioglitazone 30 mg #30 in the Baltimore metro area returns prices under $10 at multiple pharmacies.

Patients without insurance should also ask about $4 generic lists. Several Maryland pharmacy chains (Walmart, Costco, and some independent pharmacies) include pioglitazone on their $4/month or $10/90-day generic drug programs. Costco does not require a membership to use its pharmacy in Maryland, a fact many patients overlook.

Compounded Pioglitazone in Maryland

Licensed 503A compounding pharmacies in Maryland can legally prepare compounded pioglitazone formulations. This route exists primarily for patients who need a non-standard dose, a liquid formulation, or a preparation free of specific inactive ingredients (dyes, lactose, gluten-containing fillers) present in manufactured tablets.

The regulatory framework comes from the FDA's section 503A of the Federal Food, Drug, and Cosmetic Act, which permits state-licensed pharmacies to compound medications based on a valid patient-specific prescription. Maryland's Board of Pharmacy oversees these pharmacies and requires compliance with USP compounding standards.

Compounded pioglitazone pricing varies widely depending on the pharmacy, the formulation, and the quantity. Some 503A pharmacies in the Baltimore-Washington corridor price compounded pioglitazone below the retail generic cost, especially for larger 90-day fills. Others charge a compounding fee that pushes the price above generic tablet costs. Patients considering this route should request a quote from at least two compounding pharmacies and compare it against the generic tablet price at their local retail chain.

One clinical consideration: compounded oral formulations do not undergo the same FDA bioequivalence testing that manufactured generics do. The PIVENS trial (N=247 in the pioglitazone arm), which demonstrated pioglitazone 30 mg daily improved hepatic steatosis and lobular inflammation in non-alcoholic steatohepatitis (NASH) patients compared to placebo over 96 weeks, used manufactured tablets [3]. Patients using pioglitazone off-label for NASH based on PIVENS data should discuss with their prescriber whether a compounded formulation is appropriate.

Telehealth Prescribing of Pioglitazone in Maryland

Maryland permits telehealth prescribing of pioglitazone. The state updated its telehealth regulations during the COVID-19 public health emergency and made many of those flexibilities permanent through legislation signed in 2021 and extended in subsequent sessions.

A prescriber licensed in Maryland (or holding a valid multi-state compact license) can evaluate a patient via synchronous video or audio-only visit, diagnose type 2 diabetes or confirm an existing diagnosis, and write a prescription for pioglitazone that the patient fills at any Maryland pharmacy. No in-person visit is required prior to the initial telehealth prescription, though standard-of-care guidelines recommend baseline labs including HbA1c, liver function tests (ALT, AST), and a lipid panel before starting a thiazolidinedione.

The Endocrine Society's 2022 Clinical Practice Guideline on type 2 diabetes management supports pioglitazone as a second-line agent after metformin for patients who need improvement in insulin sensitivity, and notes that "careful monitoring of weight, edema, and heart failure symptoms is required during treatment." Telehealth follow-ups at 3-month intervals allow prescribers to review HbA1c trends, check for peripheral edema, and adjust dosing without requiring the patient to travel to a clinic.

For Maryland patients in rural areas of the Eastern Shore, Western Maryland, or Southern Maryland, where endocrinology offices may be 60 or more miles away, telehealth access to pioglitazone prescribing eliminates a significant barrier. Dr. Rita Kalyani, an endocrinologist at Johns Hopkins Medicine, noted in a 2023 interview with the Maryland Department of Health that "telehealth has allowed us to manage chronic conditions like diabetes with the same rigor as in-person care, and patient adherence rates have been comparable."

Off-Label Use and Cost Considerations for NASH/MASLD

Pioglitazone has a growing off-label evidence base for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NASH). The PIVENS trial (N=247, pioglitazone arm) published in the New England Journal of Medicine demonstrated that pioglitazone 30 mg daily for 96 weeks significantly improved hepatic steatosis (p<0.001), lobular inflammation (p=0.004), and the overall NAFLD Activity Score compared to placebo, though fibrosis improvement did not reach statistical significance [3].

A 2023 meta-analysis of eight randomized controlled trials (pooled N=516 pioglitazone-treated patients) published in Hepatology found that pioglitazone reduced liver fibrosis by at least one stage in 43% of patients vs. 26% on placebo (risk ratio 1.66, 95% CI 1.12 to 2.47) [4]. The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance recommends pioglitazone as a pharmacotherapy option for biopsy-proven NASH with or without type 2 diabetes.

For Maryland patients, the cost implications of off-label pioglitazone for NASH are worth examining. Insurance plans are not required to cover off-label uses, and some Maryland MCOs and commercial plans will deny a pioglitazone PA if the diagnosis code submitted is K75.81 (NASH) rather than E11.x (type 2 diabetes). Patients with both conditions should ensure the type 2 diabetes diagnosis is listed as the primary indication on the prescription to avoid unnecessary denials. Patients without diabetes who need pioglitazone for NASH may face a cash-pay scenario, but at $15 per month for generic pioglitazone, the out-of-pocket burden remains manageable.

How to Get the Lowest Price in Maryland

A step-by-step approach helps Maryland patients minimize pioglitazone costs. Start by confirming the prescription is written for generic pioglitazone, not brand-name Actos. Next, check if your insurance covers it at Tier 1 and whether your plan has a preferred pharmacy network that offers $0 copays on generics.

If you are uninsured or your copay exceeds $15, run the prescription through a discount card. GoodRx, RxSaver, and the Amazon Pharmacy discount program typically return Maryland prices between $8 and $14. Compare these against $4 generic lists at Walmart, Costco, and participating independents.

For 90-day supplies, mail-order pharmacies almost always beat 30-day retail fills. Mark Cuban's Cost Plus Drugs prices pioglitazone at its manufacturing cost plus a flat 15% markup and a $5 pharmacy fee, often yielding a 90-day supply for under $10 shipped to your Maryland address.

Patients on Maryland Medicaid pay $0 to $3 per prescription after PA approval, depending on their MCO and whether they qualify for a copay exemption based on income level.

The single most expensive mistake is filling brand-name Actos without checking generic availability. That error costs an extra $45 per month, or $540 per year, for the same molecule at the same dose producing the same clinical effect.